objective In Thailand, 7.2% of HIV patients are co-infected with hepatitis C virus (HCV), and these patients are treated with peg-interferon + ribavirin (PR) for their HCV infection. This study evaluates efficacy and safety of PR treatment and pharmacokinetics of ribavirin in this population.
Introduction
Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are both transmitted through blood-blood contact, explaining why globally~2.3 million people live with a co-infection [1] . In Thailand, it has been estimated that 7.2% of HIV patients have a co-infection with HCV. The major routes of HIV transmission are heterosexual or homosexual contact or the use of contaminated syringes and needles when using intravenous drugs [2] .
In Thai patients, HCV genotype 3 is most prevalent (43%), followed by genotype 1b (13%) [3] . Patients infected with genotype 3 respond better to treatment with peg-interferon plus ribavirin (PR) therapy than patients infected with genotype 1 [4, 5] . Conversely, when HCV is treated with all-oral therapy consisting of direct-acting antivirals (DAAs), genotype 3 is the less favourable genotype, as response rates are lower than in HCV genotype 1-infected patients [6, 7] .
In HIV/HCV co-infected patients, HIV has a negative influence on the prognosis of HCV infection, because these patients develop cirrhosis more rapidly than monoinfected patients [8] . This is especially true when they have a detectable HIV viral load [9] . In addition, co-infected patients have lower sustained virological response (SVR) rates when treated with PR than monoinfected patients. Response rates of HIV/HCV co-infected patients infected with HCV genotype 1 and 4 vary from 14% to 29%. Comparable, HCV-mono-infected patients with the same genotypes have response rates varying from 42% to 56%. The same is true for HCV genotype 2 or 3: HIV/HCV co-infected patients have response rates varying from 44 to 73%, and mono-infected patients with the same genotype have response rates varying from 75% to 84% [4] . However, with novel DAA therapy, HIV/HCV co-infected patients have similar response rates as monoinfected patients. The reported SVR rates generally exceed 95%, which is higher than with PR therapy [9] .
One explanation of lower response rates in HIV/HCV co-infected patients on PR treatment could be that these patients have suboptimal ribavirin plasma concentrations compared to mono-infected patients. This has been described by Deenen et al. [10] , who reported that the mean ribavirin plasma concentrations at week 12 of treatment were 2.62 mg/l in mono-infected and 2.14 mg/l in co-infected Western patients.
Next to lower response rates and longer treatment duration, another important disadvantage is the toxicity profile of PR. Fatigue, flu-like symptoms, neuropsychiatric events and haemolytic abnormalities are frequently reported adverse events (AEs). Severe toxicity is a common reason for lowering the dose or discontinuing PR treatment [11, 12] .
Despite the advantages of DAA treatment in coinfected patients, even for HCV genotype 3, Thai patients are still treated with PR, as DAAs remain to be expensive and not widely accessible in Thailand. Also, at the time the study began (2014), oral DAA therapy was not yet available in Thailand. This study was conducted to develop an appropriate HCV treatment programme to improve the quality of life for HIV/HCV co-infected patients in Thailand. This was a cooperation between the National Health Security Office and the Thai AIDS society. In this study, the efficacy and safety of PR treatment in Thai HIV/HCV coinfected patients is described even as the pharmacokinetics of ribavirin.
Methods

Study design
This was an open-label, prospective, multicentre, study performed in three centres in Thailand. The study design is presented in Figure 1 . All patients were treated with PR according to local Thai guidelines [13] . Depending on genotype, METAVIR score and treatment response, patients were treated for 24 or 48 weeks.
Setting
HIV/HCV co-infected patients were included from April 2014 to August 2015. Patients with any HCV genotype were eligible and treated with PR according to protocol.
Study visits were planned at baseline and week 1 (optional), 2, 4, 8, 12, 16, 20, 24, 30, 36 , 42 and 48 of treatment. In addition, 24 weeks after treatment had ended (week 72), the patient came to the study centre for determination of sustained virological response (SVR24). Patients that were treated for 24 weeks had their SVR24 visit at week 48.
During HCV treatment, all patients received adequate antiretroviral treatment for their HIV-infection according to Thai guidelines. During the study, HIV was managed by an HIV specialist and HCV was treated by a hepatologist. There was good cooperation between these two specialists.
Participants
Patients were eligible when >18 years of age and if they had a CD4 count >350 cells/ll. Cirrhotic patients were included if they had a Child-Pugh (CP) score ≤6, without ascites, hepatic encephalopathy or bleeding varices. Both males and females had to use adequate contraception during treatment and up to 24 weeks after treatment.
Patients were excluded from this study when they were allergic to peginterferon or ribavirin, had severe depression or any other psychiatric illness, known active bacterial infection, ongoing treatment for mycobacterial infection, significant liver disease other than cirrhosis, haemoglobin <11 g/dl for women or <12 g/dl for men, ALT and AST >10 times the upper limit of normal (ULN), creatinine >1.5 times the ULN, neutrophil count <1500 cells/mm 3 , platelet count <90 000 cells/mm 3 , thyroid dysfunction, use of didanosine, or evidence of severe retinopathy or any other severe illness not related to HIV/HCV co-infection (judged by the physician). Pregnant (confirmed by pregnancy test at screening) and breastfeeding women were also excluded. The study physician judged if active drugs or alcohol consumption potentially compromised treatment safety; if judged so, the patients were not eligible for inclusion.
Treatment
Patients were treated with peg-interferon alfa 2a (Pegasys â , Hoffmann-La Roche Inc, South San Francisco, CA) 180 mcg per week or peg-interferon alfa 2b (PegIntron â , Merck Sharp & Dome Corp, Whitehouse Station, NJ), which was dosed based on weight: 1.5 mcg/ kg/week. It was at the discretion of the physician whether peg-interferon alfa 2a or 2b was used. The dose of peginterferon alfa 2a was adjusted based on absolute neutrophil count (ANC) and platelet count according to the drug label.
Ribavirin 
Variables
At screening, baseline patient characteristics were collected: age, sex, height, weight, HCV genotype, HIV-and HCV RNA (RealTime HCV, Abbot Molecular). Before and during treatment, use of any concomitant medication was reported. In addition, weight, ALT, AST, haemoglobin, creatinine, white blood cell (WBC) count, platelet count, neutrophil count and lymphocyte count were determined (Table 1) . Fibroscan â was performed before and after treatment to determine the liver stiffness (kPa) and a METAVIR score [14, 15] .
SVR24 was defined as undetectable HCV RNA 24 weeks post-treatment. Week 24 or 48 were both end of treatment visits. HCV RNA was measured at week 0, 4, 12, 24 and 48 of treatment.
Information about dose adaptations, reductions and discontinuations was collected during treatment, including the reasons of these alterations.
Safety (AEs) and laboratory safety were evaluated during all study visits. AEs were graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric AEs and judged by the study physician [16] . All SAEs were reported to the Institutional Review Board (IRB) of the Faculty of Medicine, Chulalongkorn University and IRB of Bamrasnaradura Infectious Diseases Institute.
Laboratory safety parameters included haemoglobin, lymphocytes, neutrophils, platelets, WBC, creatinine, ALT and AST. Creatinine was measured as ribavirin is mainly renally cleared, and when the renal function alters, this is reflected in the ribavirin plasma concentrations. If the patients gave consent, additional blood was withdrawn to determine the ribavirin plasma concentrations at week 1, 2, 4, 8, 12, 24 and 48. Preferably, trough samples were taken; however, considering the elimination half-life of ribavirin of~300 h, this was not mandatory and other sampling times were not excluded from the analysis.
Pharmacokinetic sample analysis
Blood samples were sent to laboratory of the HIV-NAT research collaboration immediately for the analysis of ribavirin plasma concentrations. The samples were centrifuged at 3220 g for 10 min at 20°C. Plasma was divided and transferred to polypropylene tubes and stored at À20°C until analysis. Total sample processing was performed within 2 h after collection. Ribavirin plasma concentrations were determined by a validated high-performance liquid chromatography with ultraviolet detection method [17] , with a lower limit of quantification of 0.300 mg/l. The ribavirin calibration curve was linear over the concentration range of 0.300-12.000 mg/l. The within-run and between-run variations (precision) were <5%, and the accuracy values were between 95-105%.
Statistical analysis
Patient characteristics, laboratory parameters, response rate and ribavirin plasma concentrations were analysed using descriptive statistics (medians with interquartile range [IQR] or percentages). Descriptive statistics were used to analyse adaptations to the treatment, both number of dose reductions and number of treatment discontinuations. Comparably, AEs and serious AEs (SAEs) were counted.
All patients enrolled, that completed follow-up according to the study protocol, were included to calculate SVR24 rate of the cohort (percentage). Non-responders and treatment failures were also included in this efficacy analysis.
Geometric mean (GM) ribavirin plasma concentrations were calculated for week 1, 2, 4, 8, 12, 24 and 48 of treatment. Intra-and intersubject variations of ribavirin plasma concentrations were expressed as coefficient of variation (CV%). In addition, haemoglobin and ribavirin plasma concentrations were compared with independent t-test between patients with and without SVR and anaemia (haemoglobin <10 g/dl). Therefore, haemoglobin and ribavirin plasma concentrations were log-transformed and GM was reported. All statistical analyses were performed in IBM SPSS Statistics, version 22.
Ethics
Before enrolment, written informed consent was obtained from all patients. The study was approved by the local ethics committee of all three hospitals and executed in accordance with the principals of the Declaration of Helsinki and Good Clinical Practice (Bamrasnaradura Infectious Diseases Institute IRB number: P005 h/57 and HIV-NAT and Chulalongkorn Hospital IRB number: 478/56).
Results
A total of 106 patients were screened of whom 101 were eligible for inclusion (Figure 2 ). In Table 1 , the baseline characteristics of the cohort are presented. The majority of patients were male (n = 88; 87%), and most patients were infected with HCV genotype 3 (n = 46; 46%) or 1 (n = 38; 38%). Median (IQR) age and weight were 43 (38-50) years and 60 (53-70) kg, respectively. Median (IQR) baseline log10 HCV viral load was 6.13 (5.42-6.58) IU/ml. Before treatment, 68 patients had an undetectable HIV RNA load (HIV RNA of 25 patients was missing), the median (IQR) liver stiffness obtained with Fibroscan â was 11.9 (8.75-24.8) kPa, and ALT and AST were 77 (49-115) and 64 (42.5-100.5) U/l, respectively.
Treatment
With the exception of 1 patient, all responders were treated for 48 weeks (genotype 3 patients with detectable HCV RNA at week 4 or >F3 cirrhosis at baseline).
Peg-interferon alfa 2a was used by six patients (6%) and 2b was used by 95 patients (94%). All patients received, according to protocol, weight-based ribavirin ( Figure 3 ). During treatment, anaemia was reported by 28 patients (28%).
For peg-interferon 2b, the median start dose (IQR) was 1.43 (1.33-1.50) mcg/kg/week and 52 patients needed a dose reduction, resulting in a median (IQR) week 48 dose of 1.37 (1.06-1.53) mg/kg/day. For peg-interferon 2a, all patients started with a dose of 180 mcg/week and the dose was reduced for two patients to 90 mcg/week and for one patient to 135 mcg/week.
The course of ribavirin dosage, plasma haemoglobin and serum creatinine concentrations during treatment are presented in Figure 3 A total of 57 patients reached SVR24 (56%), of whom 18 (47%) had genotype 1, 29 (63%) had genotype 3, eight (57%) had genotype 6 and two (67%) had a mixed genotype. Liver enzymes normalised for the patients with SVR, median (IQR) AST and ALT of these patients at 24 weeks of follow-up were 29 (23-36) and 31 (23-42) U/l, respectively.
Of 752 AEs were reported by 101 patients of which 20 serious adverse events (SAEs). The number of AEs varied from 1 to 22 AEs per patient. The majority of AEs were graded to be mild or moderate of severity: 383 (51%) and 306 (41%), respectively. AEs were judged severe and potentially life-threatening in 48 (6%) and 10 (1%) of the cases, respectively (Table 3) .
Twenty patients discontinued treatment, of whom seven patients stopped due to (S)AEs. During the study, three patients died; one of a heroin overdose (unrelated to study medication); one of pulmonary tuberculosis (unrelated to study medication); and one of thrombocytopenia (probably related to study medication). The patient with pulmonary tuberculosis was treated with PR for 48 weeks and died after treatment, but before the SVR24 treatment visit (patient was still in HIV care). The patient with thrombocytopenia was treated for 12 weeks with PR and died 5 days after PR dose reductions. At the time, the patient had no ongoing AEs and was treated with antiretroviral therapy. At baseline, the patient had METAVIR score F4 (cirrhosis), but a CP score <6. count dropped from 1.86 to 0.63 cells 10 3 /uL during PR treatment. The patient experienced convulsions, which resulted in a coma from which the patient did not recover. At that time, the patient also had thrombocytopenia and the convulsions/coma could have been caused by an intracranial bleeding. In Table S1 , more information is given about the three deceased patients.
Ribavirin pharmacokinetics
In Figure 4 , we present the results of the pharmacokinetics of ribavirin. Ribavirin plasma concentrations were available for 39 to 64 patients (week 2 to week 48). Visual inspection of the data revealed that ribavirin steady-state plasma concentrations were reached at week 8 of treatment and the HCV treatment n Dosage-median (IQR) 
Pharmacodynamics
Regarding the sustained virological response, Table 4 shows the geometric mean ribavirin plasma concentration per week of treatment for patients with and without SVR24. A trend can be observed in which patients reaching SVR24 have slightly higher ribavirin plasma concentrations throughout treatment. This difference only reaches statistical significance at week 24 of treatment.
As Table 4 shows, patients with anaemia had higher ribavirin plasma concentrations than patients without anaemia. Until week 24, all patients with anaemia had statistically significantly higher ribavirin plasma concentrations than patients without anaemia. However, at week 48, patients with anaemia had lower ribavirin plasma concentrations.
Discussion
This is the first Thai prospective cohort study describing efficacy and safety of PR treatment in combination with Neutropaenia  62  27  29  6  Alopecia  41  1  10  30  Fatigue  34  2  12  20  Weight loss  27  3  18  6  Myalgia  25  0  11  14  Pain/rash at injection site  24  1  7  16  Anaemia  23  0  2  21  Elevated AST  21  5  16  0  Decreased lymphocytes  20  2  18  0  Anorexia  18  0  8  10  Dizziness  18  0  3  15  Nausea  17  0  6  11  Thrombocytopaenia  14  0  14  0  Insomnia  14  0  6  8  Flu-like symptoms  13  1  4  8  Loss of appetite  12  0  4  8  Depression  12  0  8  4 AST, aspartate aminotransferase.
pharmacokinetics of ribavirin in HIV/HCV co-infected patients. In this study, an overall SVR24 rate of 56% was achieved after 48 weeks of PR treatment. This SVR24 rate was relatively low, but comparable with the SVR24 rates described in genotype 2 and 3 Western coinfected patients treated with PR [4] . This could be explained by the fact that in our cohort, the majority of patients were infected with genotype 3, of whom slightly more patients achieved SVR24 than patients with genotype 1 (63% vs. 47%). The SVR24 rate of 56% is lower than in mono-infected patients [4] . It remains unclear why co-infected patients have lower response rates with PR treatment than mono-infected patients. Possibly HIV increases HCV replication [18] , induces hepatic inflammation and the release of pro-inflammatory cytokines, increases hepatic apoptosis and leads to an impaired HCV-specific immune response [19] . Remarkably, these differences in SVR24 rates disappeared with the introduction of interferon-free therapy [9] . As mentioned before, lower ribavirin plasma concentrations in co-infected vs. mono-infected patients may play a role too.
As expected with PR treatment, many AEs were reported. Most commonly reported AEs were fever, neutropaenia, alopecia, fatigue, weight loss and myalgia. These are in line with previously reported studies and resemble the known toxicity profile of PR [20, 21] . Depression and other mental disorders were only reported 21 times during this study, possibly because patients with known psychiatric illnesses were excluded from this study [20, 21] . Anaemia was the most reported SAE (n = 5). All but one of these patients experiencing anaemia as SAEs needed dose reductions of peg-interferon alfa and/or ribavirin.
Three patients died during PR treatment. Two of these deaths were unrelated to PR treatment; but one patient had severe thrombocytopaenia, which was probably related to PR treatment (PR dose was previously reduced). At the start of treatment, the patient already had a rather low platelet count, which fits the cirrhosis of the patient. Platelets are further reduced by the use of peg-interferon. Unfortunately, the dose reductions were insufficient to prevent convulsions and coma. This could have been caused by an intracranial bleeding; however, this was not confirmed by autopsy. Possibly, further dose reductions or treatment discontinuation would have been necessary.
In the light of novel DAA therapy, patients with advanced cirrhosis can be treated. These patients probably also have a lower platelet count; however, the DAAs themselves do not induce thrombocytopenia. We point out that patients with severe cirrhosis, such as CP class B/C patients, are vulnerable and that some DAAs, especially protease inhibitors, should be used with caution in these patients.
We showed that at week 8 of treatment, ribavirin reached steady-state, which fits the long elimination halflife of 300 h [22] . The steady-state ribavirin plasma concentrations found in this study were in the same range as previously published in HIV/HCV co-infected patients [10, 23, 24] . However, these plasma concentrations remained lower than reported ribavirin plasma concentrations in mono-infected patients [10, 25] . We showed that haemoglobin concentrations dropped inversely with the raise of ribavirin plasma concentrations. In addition, when steady-state was achieved, haemoglobin concentrations remained stable.
These findings fit the observation that patients with anaemia had significantly higher ribavirin plasma concentrations than patients without anaemia (until week 12). At week 24, ribavirin plasma concentrations dropped in patients with anaemia, which could be due to the large number of dose reductions that were necessary because of low haemoglobin concentrations, resulting in reduced week 48 daily dosages and ribavirin plasma concentrations. Creatinine concentrations, and thus renal function, remained stable during treatment. Thus, it appears that ribavirin renal clearance was not altered, supporting the notion that the altered ribavirin plasma concentration is caused by the dose alterations.
Only at week 24, ribavirin plasma concentrations were higher for responders than for non-responders. This could be driven by the increasing number of patients of which ribavirin plasma concentrations were available towards weekend 48. The relation between ribavirin plasma concentrations and SVR remains controversial, as both negative and positive results have been published about this topic [23, 24, [26] [27] [28] . These inconsistent results might be caused by, for example, differences in treatment, heterogeneity of populations, variation in analytical assays and small sample sizes.
A limitation of this study is that the number of ribavirin samples was varying and increasing during the study. This could potentially influence the (statical) analysis. Secondly, this was not a randomised trial comparing efficacy and safety in mono-and co-infected patients. Lastly, the drugs used in this study are considered outdated in high-income countries because of the availability of DAAs which have better safety and efficacy profiles. To date, access to expensive DAAs remains limited but could greatly improve SVR rates among HIV/HCV coinfected individuals [9] , especially velpatasvir combined with sofosbuvir (Epclusa â , Gilead Sciences, Foster City, CA), as this combination is highly active against genotype 3 [29] . Introduction of (generic) velpatasvir in Thailand would not only greatly improve SVR rates, but also it would shorten treatment duration and reduce toxicity compared with the current treatment of PR [29] .
Conclusion
PR treatment in Thai HIV/HCV co-infected patients resulted in an overall SVR rate of 56%, including hardto-treat genotype 1 patients. As known from PR therapy, toxicity was severe, but the number of patients who dropped out because of toxicity issues was small. Despite close monitoring, one vulnerable patient with cirrhosis and low platelet counts died, probably due to PR therapy. Dosages were reduced according to the drug labels, but greater dose reductions or discontinuation of both peg-interferon and ribavirin might have been necessary for this patient. Lastly, ribavirin plasma concentrations were comparable with previously published studies in HIV/HCV co-infected patients, but were lower than in mono-infected patients.
